Kathleen Victoria Fitch, M.S.N.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 88 | 2024 | 17589 | 3.310 |
Why?
|
Plaque, Atherosclerotic | 17 | 2024 | 1550 | 1.570 |
Why?
|
Quinolines | 9 | 2024 | 772 | 1.360 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 12 | 2024 | 3253 | 1.230 |
Why?
|
Cardiovascular Diseases | 25 | 2024 | 15662 | 1.220 |
Why?
|
Coronary Artery Disease | 22 | 2024 | 6569 | 1.180 |
Why?
|
HIV | 12 | 2023 | 1596 | 1.010 |
Why?
|
Sweetening Agents | 2 | 2022 | 290 | 0.840 |
Why?
|
Atherosclerosis | 9 | 2024 | 3431 | 0.690 |
Why?
|
Life Style | 5 | 2019 | 3931 | 0.680 |
Why?
|
Diet Therapy | 1 | 2019 | 150 | 0.620 |
Why?
|
Amino Acids | 3 | 2020 | 1716 | 0.610 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 5 | 2021 | 138 | 0.550 |
Why?
|
Multicenter Studies as Topic | 3 | 2020 | 1737 | 0.530 |
Why?
|
Renin-Angiotensin System | 6 | 2022 | 736 | 0.480 |
Why?
|
Monocytes | 4 | 2018 | 2603 | 0.470 |
Why?
|
Bone Diseases | 2 | 2019 | 416 | 0.430 |
Why?
|
Fibrosis | 2 | 2018 | 2081 | 0.410 |
Why?
|
Inflammation | 16 | 2024 | 10869 | 0.410 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 5 | 2018 | 283 | 0.400 |
Why?
|
Middle Aged | 77 | 2024 | 223740 | 0.400 |
Why?
|
Adiposity | 7 | 2021 | 1895 | 0.400 |
Why?
|
Tunica Media | 2 | 2011 | 111 | 0.380 |
Why?
|
Nutrition Disorders | 1 | 2011 | 204 | 0.360 |
Why?
|
Dyslipidemias | 3 | 2019 | 873 | 0.360 |
Why?
|
Asymptomatic Diseases | 5 | 2018 | 590 | 0.360 |
Why?
|
Patient Selection | 2 | 2020 | 4265 | 0.350 |
Why?
|
Subcutaneous Fat | 5 | 2019 | 403 | 0.350 |
Why?
|
Tunica Intima | 2 | 2011 | 459 | 0.330 |
Why?
|
Intra-Abdominal Fat | 4 | 2019 | 624 | 0.320 |
Why?
|
Aging | 3 | 2020 | 8765 | 0.300 |
Why?
|
Fingers | 1 | 2011 | 512 | 0.300 |
Why?
|
Metformin | 2 | 2014 | 909 | 0.300 |
Why?
|
Arteritis | 2 | 2022 | 158 | 0.290 |
Why?
|
Male | 74 | 2024 | 365249 | 0.290 |
Why?
|
Adipose Tissue | 6 | 2023 | 3335 | 0.290 |
Why?
|
Diet | 4 | 2022 | 8090 | 0.290 |
Why?
|
Neck | 2 | 2016 | 736 | 0.290 |
Why?
|
Adipose Tissue, Brown | 4 | 2019 | 776 | 0.280 |
Why?
|
Ribonuclease III | 2 | 2021 | 271 | 0.280 |
Why?
|
Risk Factors | 25 | 2024 | 74971 | 0.280 |
Why?
|
Anti-Retroviral Agents | 6 | 2023 | 1794 | 0.270 |
Why?
|
Cytomegalovirus Infections | 2 | 2024 | 839 | 0.270 |
Why?
|
Anti-HIV Agents | 9 | 2020 | 4576 | 0.270 |
Why?
|
Carotid Arteries | 1 | 2011 | 943 | 0.270 |
Why?
|
Female | 74 | 2024 | 397464 | 0.270 |
Why?
|
Humans | 99 | 2024 | 768887 | 0.260 |
Why?
|
Viral Nonstructural Proteins | 1 | 2018 | 228 | 0.260 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2022 | 10397 | 0.260 |
Why?
|
Adult | 49 | 2024 | 223818 | 0.260 |
Why?
|
DEAD-box RNA Helicases | 2 | 2021 | 385 | 0.260 |
Why?
|
Calcinosis | 2 | 2012 | 1481 | 0.250 |
Why?
|
Body Composition | 12 | 2019 | 2461 | 0.250 |
Why?
|
Drug Resistance, Viral | 2 | 2023 | 869 | 0.240 |
Why?
|
Risk Reduction Behavior | 1 | 2011 | 1119 | 0.240 |
Why?
|
Receptors, Cell Surface | 5 | 2018 | 2820 | 0.230 |
Why?
|
HIV Integrase Inhibitors | 2 | 2023 | 165 | 0.220 |
Why?
|
Lipoproteins, LDL | 4 | 2024 | 643 | 0.220 |
Why?
|
Antigens, CD | 5 | 2018 | 4032 | 0.210 |
Why?
|
Nutritional Status | 1 | 2011 | 1627 | 0.210 |
Why?
|
Viral Load | 8 | 2022 | 3398 | 0.210 |
Why?
|
Insulin Resistance | 6 | 2021 | 3982 | 0.210 |
Why?
|
Exercise | 1 | 2019 | 5953 | 0.210 |
Why?
|
Sex Factors | 7 | 2019 | 10641 | 0.210 |
Why?
|
Body Mass Index | 10 | 2023 | 13054 | 0.200 |
Why?
|
HIV Integrase | 1 | 2023 | 122 | 0.200 |
Why?
|
Proteinuria | 1 | 2024 | 610 | 0.190 |
Why?
|
Blood Proteins | 3 | 2023 | 1191 | 0.180 |
Why?
|
Subcutaneous Fat, Abdominal | 2 | 2019 | 91 | 0.180 |
Why?
|
Hepacivirus | 1 | 2018 | 1344 | 0.180 |
Why?
|
Albuminuria | 1 | 2024 | 658 | 0.180 |
Why?
|
Prevalence | 8 | 2024 | 15875 | 0.180 |
Why?
|
HIV-1 | 6 | 2023 | 6963 | 0.170 |
Why?
|
HIV Long-Term Survivors | 1 | 2020 | 140 | 0.170 |
Why?
|
Proteomics | 4 | 2023 | 3913 | 0.170 |
Why?
|
Hyperinsulinism | 2 | 2017 | 402 | 0.170 |
Why?
|
Cross-Sectional Studies | 10 | 2024 | 26384 | 0.160 |
Why?
|
Hypoglycemic Agents | 1 | 2012 | 3110 | 0.160 |
Why?
|
AIDS-Associated Nephropathy | 1 | 2019 | 34 | 0.160 |
Why?
|
Endothelium, Vascular | 1 | 2011 | 4428 | 0.160 |
Why?
|
Serum | 2 | 2019 | 207 | 0.160 |
Why?
|
Absorptiometry, Photon | 2 | 2019 | 1757 | 0.150 |
Why?
|
Research Subjects | 1 | 2020 | 249 | 0.150 |
Why?
|
Coronary Angiography | 6 | 2024 | 4541 | 0.150 |
Why?
|
Comorbidity | 5 | 2020 | 10591 | 0.150 |
Why?
|
Heart Diseases | 1 | 2011 | 2819 | 0.150 |
Why?
|
Methylamines | 2 | 2016 | 136 | 0.150 |
Why?
|
Young Adult | 15 | 2021 | 60110 | 0.150 |
Why?
|
Anti-Mullerian Hormone | 1 | 2020 | 420 | 0.140 |
Why?
|
Hepatitis C | 1 | 2018 | 1595 | 0.140 |
Why?
|
Aged | 21 | 2024 | 171790 | 0.140 |
Why?
|
Cholesterol, LDL | 5 | 2024 | 2402 | 0.140 |
Why?
|
Natriuretic Peptides | 1 | 2018 | 156 | 0.140 |
Why?
|
Tomography, X-Ray | 1 | 2016 | 58 | 0.140 |
Why?
|
Angiography | 3 | 2016 | 1598 | 0.130 |
Why?
|
Food Supply | 1 | 2022 | 544 | 0.130 |
Why?
|
CD4 Lymphocyte Count | 5 | 2020 | 2598 | 0.130 |
Why?
|
Reverse Transcriptase Inhibitors | 3 | 2022 | 622 | 0.130 |
Why?
|
Smoking | 1 | 2013 | 9094 | 0.130 |
Why?
|
Adolescent | 18 | 2021 | 89247 | 0.130 |
Why?
|
Muscle Cells | 1 | 2016 | 195 | 0.130 |
Why?
|
Sodium | 2 | 2022 | 1597 | 0.130 |
Why?
|
Triglycerides | 3 | 2020 | 2464 | 0.120 |
Why?
|
Antiviral Agents | 1 | 2018 | 3069 | 0.120 |
Why?
|
Double-Blind Method | 8 | 2024 | 12469 | 0.120 |
Why?
|
Macrophage Activation | 1 | 2018 | 556 | 0.120 |
Why?
|
Pravastatin | 1 | 2017 | 393 | 0.120 |
Why?
|
Nutrition Policy | 1 | 2019 | 467 | 0.120 |
Why?
|
Diet Surveys | 1 | 2019 | 1160 | 0.120 |
Why?
|
Coronary Vessels | 4 | 2023 | 3124 | 0.120 |
Why?
|
Glomerular Filtration Rate | 2 | 2020 | 2228 | 0.120 |
Why?
|
Interleukin-10 | 1 | 2020 | 1184 | 0.110 |
Why?
|
Gender Identity | 1 | 2020 | 770 | 0.110 |
Why?
|
Behavior Therapy | 1 | 2019 | 886 | 0.110 |
Why?
|
Diabetes Mellitus | 2 | 2024 | 5892 | 0.110 |
Why?
|
Regression Analysis | 3 | 2013 | 6346 | 0.110 |
Why?
|
International Cooperation | 1 | 2020 | 1436 | 0.110 |
Why?
|
Blood Coagulation Disorders | 1 | 2016 | 350 | 0.110 |
Why?
|
Cholesterol, HDL | 2 | 2013 | 1820 | 0.110 |
Why?
|
Pericardium | 1 | 2018 | 679 | 0.110 |
Why?
|
Adipose Tissue, White | 1 | 2016 | 371 | 0.100 |
Why?
|
Minority Groups | 1 | 2020 | 1216 | 0.100 |
Why?
|
Boston | 2 | 2019 | 9375 | 0.100 |
Why?
|
Chemokine CXCL10 | 1 | 2013 | 312 | 0.100 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2023 | 127 | 0.100 |
Why?
|
Anticholesteremic Agents | 2 | 2017 | 972 | 0.100 |
Why?
|
Menopause | 1 | 2020 | 1656 | 0.100 |
Why?
|
Sex Characteristics | 2 | 2023 | 2660 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 7 | 2019 | 20776 | 0.090 |
Why?
|
Fenofibrate | 1 | 2011 | 87 | 0.090 |
Why?
|
Cardiovascular System | 1 | 2018 | 840 | 0.090 |
Why?
|
Fibronectins | 1 | 2014 | 724 | 0.090 |
Why?
|
Case-Control Studies | 7 | 2020 | 22294 | 0.090 |
Why?
|
Niacin | 1 | 2011 | 117 | 0.090 |
Why?
|
Intestinal Diseases | 1 | 2015 | 505 | 0.090 |
Why?
|
Proteome | 1 | 2020 | 1891 | 0.090 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2018 | 1942 | 0.090 |
Why?
|
Iodide Peroxidase | 1 | 2012 | 295 | 0.090 |
Why?
|
Prospective Studies | 8 | 2022 | 54950 | 0.090 |
Why?
|
Osteoporosis | 1 | 2019 | 1606 | 0.090 |
Why?
|
Pulsatile Flow | 1 | 2011 | 320 | 0.090 |
Why?
|
Hyperemia | 1 | 2011 | 224 | 0.080 |
Why?
|
Drug Therapy, Combination | 2 | 2018 | 6320 | 0.080 |
Why?
|
Vaccination | 1 | 2022 | 3436 | 0.080 |
Why?
|
North America | 2 | 2024 | 1290 | 0.080 |
Why?
|
Vitamin D Deficiency | 1 | 2019 | 1388 | 0.080 |
Why?
|
Cytomegalovirus | 2 | 2024 | 753 | 0.080 |
Why?
|
Primary Prevention | 3 | 2023 | 1187 | 0.080 |
Why?
|
Calorimetry, Indirect | 1 | 2009 | 176 | 0.080 |
Why?
|
Mass Spectrometry | 1 | 2016 | 2204 | 0.080 |
Why?
|
Manometry | 1 | 2011 | 459 | 0.080 |
Why?
|
Fibroblast Growth Factors | 1 | 2014 | 873 | 0.080 |
Why?
|
Blood Pressure | 4 | 2018 | 8541 | 0.080 |
Why?
|
Lipodystrophy | 2 | 2006 | 145 | 0.080 |
Why?
|
Blood Glucose | 3 | 2021 | 6434 | 0.070 |
Why?
|
Cardiomyopathies | 1 | 2020 | 2057 | 0.070 |
Why?
|
Patient Participation | 1 | 2017 | 1448 | 0.070 |
Why?
|
Immunologic Factors | 1 | 2017 | 1597 | 0.070 |
Why?
|
Antibodies, Viral | 3 | 2024 | 3216 | 0.070 |
Why?
|
Stavudine | 1 | 2007 | 85 | 0.070 |
Why?
|
Extremities | 1 | 2012 | 870 | 0.070 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2012 | 2056 | 0.070 |
Why?
|
Placebos | 2 | 2024 | 1668 | 0.070 |
Why?
|
Adipogenesis | 2 | 2021 | 371 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2297 | 0.060 |
Why?
|
Hyperlipidemias | 1 | 2011 | 773 | 0.060 |
Why?
|
Mitochondria, Muscle | 1 | 2007 | 172 | 0.060 |
Why?
|
Hypertension | 2 | 2019 | 8615 | 0.060 |
Why?
|
Liver | 2 | 2021 | 7579 | 0.060 |
Why?
|
Immunity | 1 | 2011 | 1003 | 0.060 |
Why?
|
Energy Metabolism | 3 | 2016 | 2905 | 0.060 |
Why?
|
Treatment Outcome | 8 | 2018 | 65485 | 0.060 |
Why?
|
MicroRNAs | 1 | 2021 | 3811 | 0.060 |
Why?
|
Cholesterol | 1 | 2014 | 2913 | 0.060 |
Why?
|
Vitamin D | 1 | 2019 | 3311 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3709 | 0.060 |
Why?
|
Health Promotion | 1 | 2017 | 2210 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3438 | 0.060 |
Why?
|
RNA, Messenger | 1 | 2019 | 12809 | 0.060 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2019 | 878 | 0.060 |
Why?
|
Age Factors | 3 | 2020 | 18454 | 0.060 |
Why?
|
Chemokine CCL2 | 2 | 2017 | 606 | 0.060 |
Why?
|
Heart | 1 | 2017 | 4448 | 0.060 |
Why?
|
Back | 2 | 2016 | 64 | 0.060 |
Why?
|
Exercise Therapy | 1 | 2011 | 938 | 0.060 |
Why?
|
Aldosterone | 2 | 2022 | 881 | 0.060 |
Why?
|
Diet, Sodium-Restricted | 2 | 2016 | 291 | 0.060 |
Why?
|
Wounds and Injuries | 1 | 2016 | 2517 | 0.050 |
Why?
|
Body Size | 1 | 2006 | 463 | 0.050 |
Why?
|
Glucose Clamp Technique | 2 | 2018 | 263 | 0.050 |
Why?
|
Waist Circumference | 2 | 2019 | 935 | 0.050 |
Why?
|
Protease Inhibitors | 1 | 2006 | 752 | 0.050 |
Why?
|
Up-Regulation | 1 | 2012 | 4148 | 0.050 |
Why?
|
United States | 5 | 2023 | 73180 | 0.050 |
Why?
|
Lipids | 2 | 2018 | 3345 | 0.050 |
Why?
|
Eating | 1 | 2009 | 1542 | 0.050 |
Why?
|
Nucleosides | 1 | 2022 | 131 | 0.050 |
Why?
|
CCN Intercellular Signaling Proteins | 1 | 2021 | 24 | 0.050 |
Why?
|
Latent TGF-beta Binding Proteins | 1 | 2021 | 45 | 0.050 |
Why?
|
Lymphocyte Activation | 1 | 2012 | 5505 | 0.050 |
Why?
|
Immunoglobulin G | 2 | 2024 | 4568 | 0.050 |
Why?
|
Treatment Failure | 1 | 2018 | 2663 | 0.050 |
Why?
|
Risk Assessment | 4 | 2022 | 24330 | 0.050 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2005 | 383 | 0.050 |
Why?
|
Obesity | 2 | 2022 | 13087 | 0.050 |
Why?
|
CD4-CD8 Ratio | 1 | 2020 | 114 | 0.040 |
Why?
|
Statistical Distributions | 1 | 2020 | 63 | 0.040 |
Why?
|
Obesity, Abdominal | 2 | 2015 | 375 | 0.040 |
Why?
|
Receptors, Purinergic P2X5 | 1 | 2019 | 7 | 0.040 |
Why?
|
Reproduction | 2 | 2020 | 646 | 0.040 |
Why?
|
Muscle, Skeletal | 2 | 2023 | 4980 | 0.040 |
Why?
|
Integrases | 1 | 2022 | 520 | 0.040 |
Why?
|
Oxygen Consumption | 1 | 2006 | 1883 | 0.040 |
Why?
|
Ultrasonography | 2 | 2011 | 6001 | 0.040 |
Why?
|
Amino Acid Transport Systems, Neutral | 1 | 2019 | 42 | 0.040 |
Why?
|
Massachusetts | 1 | 2013 | 8888 | 0.040 |
Why?
|
Dietary Fats | 1 | 2007 | 2003 | 0.040 |
Why?
|
Glucose | 2 | 2012 | 4352 | 0.040 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4123 | 0.040 |
Why?
|
Interleukin-18 | 1 | 2021 | 251 | 0.040 |
Why?
|
Muscles | 1 | 2024 | 1582 | 0.040 |
Why?
|
Positron-Emission Tomography | 2 | 2012 | 6673 | 0.040 |
Why?
|
Phenotype | 1 | 2016 | 16735 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2009 | 12093 | 0.040 |
Why?
|
Alanine Transaminase | 1 | 2021 | 606 | 0.040 |
Why?
|
HIV Protease Inhibitors | 1 | 2019 | 432 | 0.040 |
Why?
|
Cohort Studies | 5 | 2021 | 41800 | 0.040 |
Why?
|
Receptors, Interleukin-1 | 1 | 2018 | 260 | 0.030 |
Why?
|
Blood Chemical Analysis | 1 | 2019 | 436 | 0.030 |
Why?
|
Symporters | 1 | 2019 | 363 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2022 | 811 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2020 | 1903 | 0.030 |
Why?
|
Hormones | 2 | 2014 | 871 | 0.030 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2018 | 199 | 0.030 |
Why?
|
Transsexualism | 1 | 2020 | 210 | 0.030 |
Why?
|
Galectin 3 | 1 | 2018 | 240 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2021 | 1328 | 0.030 |
Why?
|
History, 21st Century | 1 | 2022 | 1575 | 0.030 |
Why?
|
Radiography, Abdominal | 1 | 2019 | 541 | 0.030 |
Why?
|
Malnutrition | 1 | 2022 | 631 | 0.030 |
Why?
|
Galectins | 1 | 2018 | 295 | 0.030 |
Why?
|
Gene Expression | 2 | 2019 | 7602 | 0.030 |
Why?
|
Gene Silencing | 1 | 2021 | 1505 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2020 | 3782 | 0.030 |
Why?
|
Adipocytes | 1 | 2021 | 1199 | 0.030 |
Why?
|
Body Fat Distribution | 1 | 2016 | 246 | 0.030 |
Why?
|
Glucose Tolerance Test | 1 | 2017 | 1183 | 0.030 |
Why?
|
Down-Regulation | 1 | 2021 | 2941 | 0.030 |
Why?
|
Genotype | 1 | 2018 | 13048 | 0.030 |
Why?
|
Choline | 1 | 2015 | 522 | 0.030 |
Why?
|
Income | 1 | 2021 | 1878 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2016 | 1539 | 0.020 |
Why?
|
Angiotensin II | 1 | 2015 | 844 | 0.020 |
Why?
|
Community Health Services | 1 | 2017 | 659 | 0.020 |
Why?
|
Spleen | 1 | 2017 | 2294 | 0.020 |
Why?
|
RNA, Viral | 1 | 2020 | 2871 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2016 | 1866 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1794 | 0.020 |
Why?
|
Drug Interactions | 1 | 2015 | 1421 | 0.020 |
Why?
|
Self Report | 1 | 2022 | 3773 | 0.020 |
Why?
|
Abdominal Fat | 1 | 2012 | 221 | 0.020 |
Why?
|
Mesenchymal Stem Cells | 1 | 2021 | 1672 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2021 | 2986 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2023 | 4413 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2020 | 2122 | 0.020 |
Why?
|
Hypertrophy | 1 | 2012 | 562 | 0.020 |
Why?
|
American Heart Association | 1 | 2014 | 1051 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2013 | 12252 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2022 | 3626 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2014 | 1560 | 0.020 |
Why?
|
Communication | 1 | 2022 | 3908 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2021 | 4940 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2018 | 3233 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2012 | 2299 | 0.020 |
Why?
|
Health Status | 1 | 2020 | 4095 | 0.020 |
Why?
|
Body Constitution | 1 | 2007 | 273 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2017 | 2339 | 0.020 |
Why?
|
Atrophy | 1 | 2012 | 1647 | 0.020 |
Why?
|
Phosphocreatine | 1 | 2007 | 261 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2021 | 14485 | 0.020 |
Why?
|
Carotid Artery, Common | 1 | 2006 | 175 | 0.020 |
Why?
|
Phosphorus | 1 | 2007 | 336 | 0.020 |
Why?
|
Research Design | 1 | 2020 | 6213 | 0.010 |
Why?
|
Hypertriglyceridemia | 1 | 2007 | 293 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2021 | 11684 | 0.010 |
Why?
|
Menstruation | 1 | 2005 | 310 | 0.010 |
Why?
|
Homeostasis | 1 | 2014 | 3348 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8745 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2019 | 7885 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2007 | 1328 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2019 | 9618 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2023 | 11521 | 0.010 |
Why?
|
Thorax | 1 | 2005 | 557 | 0.010 |
Why?
|
Protons | 1 | 2007 | 1113 | 0.010 |
Why?
|
DNA, Mitochondrial | 1 | 2007 | 871 | 0.010 |
Why?
|
Contrast Media | 1 | 2014 | 5334 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 8055 | 0.010 |
Why?
|
Ovary | 1 | 2005 | 965 | 0.010 |
Why?
|
Anthropometry | 1 | 2005 | 1343 | 0.010 |
Why?
|
Transcription Factors | 1 | 2019 | 12174 | 0.010 |
Why?
|
Biopsy | 1 | 2012 | 6805 | 0.010 |
Why?
|
Energy Intake | 1 | 2007 | 2146 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9549 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2014 | 7460 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 11934 | 0.010 |
Why?
|
Disease Progression | 1 | 2012 | 13677 | 0.010 |
Why?
|
Radiography | 1 | 2006 | 6991 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2020 | 59738 | 0.010 |
Why?
|
Mice | 1 | 2021 | 82074 | 0.010 |
Why?
|
Prognosis | 1 | 2015 | 30044 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2007 | 7860 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36861 | 0.010 |
Why?
|
Bone Density | 1 | 2005 | 3573 | 0.010 |
Why?
|
Animals | 1 | 2021 | 169408 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2005 | 14795 | 0.000 |
Why?
|
Neoplasms | 1 | 2017 | 22390 | 0.000 |
Why?
|